Compare DOO & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOO | AMRX |
|---|---|---|
| Founded | 1937 | 2002 |
| Country | Canada | United States |
| Employees | 17000 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.0B |
| IPO Year | N/A | 2018 |
| Metric | DOO | AMRX |
|---|---|---|
| Price | $59.44 | $16.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $85.67 | $15.60 |
| AVG Volume (30 Days) | 159.9K | ★ 2.2M |
| Earning Date | 05-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $8.48 | $4.48 |
| Revenue Next Year | $5.10 | $7.13 |
| P/E Ratio | $338.95 | ★ $89.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.83 | $7.67 |
| 52 Week High | $81.89 | $17.86 |
| Indicator | DOO | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 68.98 |
| Support Level | $56.69 | $12.46 |
| Resistance Level | $63.73 | $17.86 |
| Average True Range (ATR) | 1.83 | 0.54 |
| MACD | -0.28 | -0.13 |
| Stochastic Oscillator | 39.71 | 54.92 |
BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which has largely been divested; Manitou was sold in the third quarter of fiscal 2026, and Telwater remains up for sale. At the end of fiscal 2026, the company sold its products through a network of more than 2,050 independent dealers and 140 distributors in around 110 countries.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.